May 07, 2026 -- SK pharmteco today announced a strategic partnership with Axle Informatics and the National Institutes of Health (NIH) to advance the development of gene therapies for rare diseases. This partnership, focused on viral vector programs, underscores SK pharmteco’s commitment to the rare disease sector and its role as a key technical partner for leading research institutions. As a subcontractor to the NIH, SK pharmteco is working with Axle Informatics, the NIH’s primary contractor,

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the successful completion of the acquisition of Terns Pharmaceuticals, Inc. (“Terns”) (Nasdaq: TERN). “The Terns acquisition reflects Merck’s continued focus on science‑driven, value‑enhancing business development aimed at bringing meaningful innovation to patients,” said Robert M. Davis, chairman and chief executive officer, Merck. “We believe TERN‑701 has the potential to become a differentiated treatment

Strategic investment brings together RTI's scientific leadership and Navidence AI-native platform to improve research quality, reproducibility, and patient outcomes across the life sciences May 5, 2026 -- Independent scientific research institute RTI International today announced a partnership and strategic equity investment in Navidence, a technology and knowledge content company focused on defining health data and enabling more efficient, transparent and scientifically rigorous clinical resea

AI-Driven Field Insights Drive Pharmaceutical Brand Performance in World’s Largest Market April 30, 2026 -- KAI Conversations, an AI-powered conversation intelligence platform purpose-built for the pharmaceutical industry, today announced a strategic partnership with Syneos Health®, a leading fully integrated biopharmaceutical solutions organization, to bring AI-driven field insights to the U.S. biopharma market. Pharmaceutical companies invest an estimated 30–50% of revenue in field teams,

China-based Huahui Health has granted BeOne Medicines (Nasdaq: ONC) a global exclusive option over HH160, a preclinical trispecific antibody targeting PD-1, CTLA-4, and VEGF-A simultaneously, in a cancer immunotherapy collaboration that carries a headline value of up to USD 2.02 billion. Under the agreement, BeOne Medicines (NASDAQ: ONC) pays an upfront USD 20 million to secure the option, with a further USD 100 million due upon formal exercise. Huahui Health, a privately held Beijing-based biop

ERAPs (ERAP1 and ERAP2) are emerging therapeutic targets associated with multiple autoimmune diseases. Genomics will assemble the largest available genetic resource to evaluate how ERAP variants influence an individual's risk of developing multiple autoimmune diseases. Insights will be used to strengthen Greywolf Therapeutics' autoimmune disease pipeline. April 29, 2026 -- Genomics, a science-led techbio company using large-scale genetic information to accelerate drug discovery and development

Transaction establishes global ownership rights of lead program and includes initial capital funding with additional optional milestone-based capital support aligned with key clinical milestones. April 24, 2026 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer and age-related diseases, today announced the successful closing of its previously announced acq

– Regulatory Filing in Japan Planned Following Clinical Trial Completion – April 24, 2026 -- Kyowa Kirin Co., Ltd. (TSE: 4151, “Kyowa Kirin”) and Kura Oncology, Inc. (Nasdaq: KURA, “Kura”) today announced the first patient has been dosed in a Japanese Phase 2 registrational clinical trial (jRCT2031250550) studying ziftomenib, an oral menin inhibitor, for the treatment of relapsed or refractory (R/R) NPM1-mutated (NPM1-m) acute myeloid leukemia (AML). NPM1-m AML accounts for approximately 30% of

Strategic collaboration creates a seamless US-APAC manufacturing corridor, enabling local production for global clinical trials and enhancing patient access to next-generation medicines. April 21, 2026 -- Andelyn Biosciences, ("Andelyn") a leading and patient-focused cell and gene therapy Contract Development and Manufacturing Organization ("CDMO"), and ENCell Co., Ltd. ("ENCell"), a Korea-based advanced biopharmaceutical CDMO, announced today the signing of a Collaboration Agreement to establi

April 20, 2026 -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it has completed its acquisition of CathWorks, a privately held medical device company, which aims to transform how coronary artery disease (CAD) is diagnosed and treated. The acquisition follows a 2022 strategic partnership with a co-promotion agreement for the CathWorks FFRangio® System where it is commercially available in the U.S., Europe and Japan. The acquisition is valued at $585 million